Very cheap is relative. Zystor was paid $22m upfront and upto 93m milestones for an enzyme replacement therapy. The market value of the theraphy is smaller than Acromegaly and Sight Disorder. Also the antisense technology is miles ahead compare to enzyme theraphy.
Also of note that the deal was done at Pre-clinical trial in Aug 2010 and that Zystor has since operating as a subsidiary of BioMarin. So it was essentially a Buyout of a private company, which is similar to Excalliard by Pfizer.
To buy out ANP, a public company, I would expect multiple times of the 20c startup SP. At this stage I would gladly accept a 40cps buyout. :$
anp broker report - buysellsignals, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |